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Introduction
The guidelines project is a joint initiative of the Associação Médica Brasileira and 
the Conselho Federal de Medicina. It aims to bring information together in medicine to 
standardize decisions in order to help strategies during diagnosis and treatment. These 
data were prepared and recommended by the Associação Brasileira de Hematologia, 
Hemoterapia e Terapia Celular (ABHH). Even though, all possible decisions should be 
evaluated by the physician responsible for diagnosis and treatment according to the patient’s 
setting and clinical status.
Description of the evidence collection method
The members of the ABHH Committee responsible for writing the diagnostic 
guidelines on primary immune thrombocytopenia (ITP) prepared the main questions related 
to the clinical diagnosis of children and adolescents. Seven questions were structured 
using the Patient/Problem, Intervention, Comparison and Outcome (PICO) system. The 
search strategies for specific clinical questions (Appendix 1) were applied to the key 
scientific databases (MEDLINE PubMed, Embase, SciELO, Lilacs and Cochrane Library) 
for publications up to 2012. The retrieved articles were submitted to a critical appraisal 
and categorized according to its strength of evidence, giving support to elaborate the 
answers to the questions. Each selected reference was classified according to the degree of 
recommendation using the Oxford Classification(1). Each recommendation was discussed by 
the committee and a consensus was attained. The development of these recommendations 
was completed supervised by experts on evidence-based guidelines.
Recommendation degree and evidence level
A: Experimental or observational studies of better consistency
B: Experimental or observational studies less consistent
C: Case reports (uncontrolled studies)
D: Opinion without critical evaluation based on consensus, physiological studies or 
animal models
Aims
To define parameters for the clinical and laboratory diagnoses and evaluate the risk of 
bleeding in children and adolescents with ITP based on the best available published evidence. 
The target audience is the hematologist, pediatrician and medical student.
Background
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disease where the 
platelet count is < 100 x 109/L. Nowadays the immune etiology is well known and not every 
patient suffers from bleeding and so the terms ‘idiopathic’ and ‘purpura’ should be avoided(2)
(D). In ITP, other causes of thrombocytopenia are not observed and the main problem is the 
bleeding. Secondary ITP involves immune-mediated forms of thrombocytopenia, such as 
systemic lupus erythematosus, human immunodeficiency virus (HIV), hepatitis C, drugs, and 
Helicobacter pylori, among others(2-4)(D).
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When is primary immune thrombocytopenia 
considered acute, chronic or persistent?
The term acute ITP has recently been replaced by newly 
diagnosed ITP. It is defined when the platelet count is low for less 
than three months. Persistent ITP refers to patients who have not 
achieved remission or not maintained their response to treatment 
for a period between three and 12 months after diagnosis. When 
there is no remission of thrombocytopenia 12 months after 
diagnosis, it is considered chronic(2)(D).
The terms acute and chronic ITP will be maintained because 
older publications published before the introduction of the current 
terminology were used to write these guidelines. Thus, for older 
studies, acute ITP and chronic ITP are used for cases with up 
to six months and more than six months of thrombocytopenia, 
respectively.
Newly diagnosed ITP in children is usually preceded 
by viral infections and the patient exhibits thrombocytopenia 
(< 100 x 109 platelets/L), petechiae and bruises. About 80% of these 
patients have spontaneous remission within the first six months 
after diagnosis; of the remaining 20% of cases, more than 50% 
have spontaneous remission within the first four years, i.e. platelet 
count normalizes each year in 10 to 15% of the patients(4)(D).
Thrombocytopenia persists for more than six months in 
33% of children with ITP and for more than 12 months in 10%(5)
(D). Platelet counts normalize (above 150 x 109 platelets/L) 
by 12 months in about 25.6% of the children who are still 
thrombocytopenic six months after diagnosis(6)(B). Ten to 30% 
of children who have chronic ITP at six months of follow-up 
achieve remission after this period(7)(B). Therefore, the follow-
up of patients with ITP demonstrates spontaneous remission of 
thrombocytopenia in 50% of the cases in between six and 12 
months, and so it is more appropriate to define chronic ITP as 
thrombocytopenia that persists for more than 12 months(8)(B).
The characteristics of chronic ITP patients are age older than 
10 years, insidious onset of symptoms more than two weeks prior 
to diagnosis, skin and oral mucosa bleeding and platelet count > 
20 x 109/L(9)(B). 
Insidious onset of bleeding more than 14 days before 
diagnosis is a predictive factor associated with chronic compared 
to acute ITP(10)(B). Symptoms lasting for more than 14 days 
before diagnosis suggest the chronic form of the disease(11)(B). 
The proportion of cases of chronic ITP increases with age at 
diagnosis. The mean age of patients with chronic ITP at the time 
of diagnosis (ten years) was greater than that of patients with 
acute ITP (5.1 years). Mucosal bleeding was more common in 
patients with acute disease (50%) than those with chronic disease 
(23%; p-value = 0.002)(12)(B).
In patients diagnosed with ITP, some factors are significantly 
associated with the probability that the thrombocytopenia is acute 
or chronic. ITP is more likely to be chronic when the child’s age 
is greater than ten years (41%) or the platelet count is greater 
than 50 x 109/L (45%); if these two conditions are combined, the 
chance of chronic disease is 50%. ITP is acute in 84% of under 
ten-year-old patients with a platelet count of less than 50 x 109/L. 
The chance that the ITP is acute is 93% in patients younger than 
12 months(13)(B).
Recommendation: Acute ITP or newly-diagnosed ITP is 
characterized by a platelet count of less than 100 x 109/L and 
often by petechiae and bruises; bleeding is usually more intense 
within the three months following diagnosis. When remission 
is not attained or response to treatment is not sustained in 
three to 12 months, it is considered persistent ITP. When the 
thrombocytopenia persists for more than 12 months, ITP is 
considered chronic. Some diagnostic factors that suggest the 
chronic form are age older than ten years, platelet count greater 
than 50 x 109/L, mild bleeding and insidious onset of symptoms 
for more than 14 days prior to diagnosis.
What are the criteria that must be present for 
the definition of refractory primary immune 
thrombocytopenia and for complete and partial 
remission?
The definition of complete remission or complete response 
to treatment is a platelet count ≥ 100 x 109/L with no clinically 
relevant bleeding. The definition of remission or partial response 
is a platelet count between 30 and 100 x 109/L or double the 
baseline platelet count with no clinically relevant bleeding. 
Refractory ITP occurs when there is splenectomy failure 
associated to severe ITP. Severe ITP is considered when bleeding 
is occuring at diagnosis and requires treatment, or when new sites 
of bleeding requiring increased doses of or changes in medication 
appear. Treatment failure occurs when platelet count remains 
< 30 x 109/L in two different measurements or when the increase 
in platelet count is less than twice the baseline value(14-16)(D). 
So that the concept of response is not exclusively based on the 
platelet count, as bleeding resolution should also be considered. 
There are recommendations to avoid the terms ‘partial’ or 
‘minimal’ response due to the criterion heterogeneity. The idea 
of refractoriness is based on the expectancy that a response to 
splenectomy occurs in 60% of cases(2)(D). 
In another ITP study, the definition used for complete response 
was platelet count ≥ 100 x 109/L for more than three months without 
treatment, partial remission was platelet count between 50 and 90 x 
109/L for more than three months without treatment, active disease 
when platelet was < 50 x 109/L with or without treatment and 
spontaneous remission when it occurs without splenectomy(17)(C).
Recommendation: The definition of complete spontaneous 
remission or complete response to treatment is a platelet count 
≥ 100 x 109/L without clinically significant bleeding. Partial 
spontaneous remission or partial response to treatment is a 
platelet count between 30 and 100 x 109/L or twice the baseline 
platelet count and again without clinically significant bleeding. 
Refractory ITP is related to splenectomy failure with maintenance 
of severe ITP. This last definition does not apply to patients with 
accessory spleen. Response failure occurs when the platelet count 
is < 30 x 109/L in two different measurements or the increase in 
platelets is less than twice the baseline value.
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 When should the diagnosis of primary 
immune thrombocytopenia in a patient with 
thrombocytopenia be considered? At what platelet 
count should primary immune thrombocytopenia be 
investigated?
The mean platelet count in healthy children aged six months 
to 18 years old was observed to be 279 x 109 platelets/L ± 51 x 
109 platelets/L(18)(C).
A platelet count less than 100 x 109/L suggests the diagnosis 
of ITP. In certain populations, a platelet count between 100 and 
150 x 109/L can be considered normal(2,15)(D).
Besides a platelet count less than 100 x 109/L, it is 
recommended that the patient should be followed up for a period 
of two to six months or to have two low platelet counts for the 
diagnosis of ITP (19,20)(D).
Recommendation: For the diagnosis of ITP, the platelet count 
must be less than 100 x 109/L. If the patient is asymptomatic, 
thrombocytopenia should be confirmed with two further 
measurements and clinical follow-up of two to six months.
Is there evidence to support bone marrow 
examination to confirm diagnosis of primary 
immune thrombocytopenia? When is a bone marrow 
examination indicated?
In thrombocytopenic patients, a bone marrow examination 
allows a differential diagnosis between bone marrow diseases and 
unrelated diseases(21)(B). A bone marrow aspirate is recommended 
for patients who have clinical findings (splenomegaly) with an 
atypical blood count (anemia, neutropenia)(3)(D). Bone marrow 
aspirate in children with suspected ITP should be made when 
corticosteroid use is considered vital(3,22)(D)(23)(C).
Differential diagnosis between ITP and inherited 
thrombocytopenia in children can be attained through 
an investigation of the family history and an analysis 
of peripherical blood cells. In this case, a bone marrow 
examination plays a small role(24)(C).
In children older than six months with ITP there is no 
difference in quality of life whether a bone marrow aspirate is 
performed at diagnosis or only in high risk patients (pancytopenia) 
or whether it is not collected(25)(C).
In 332 children between six months and 18 years old with 
initial diagnosis of ITP (50 x 109 platelets/L without further 
changes in the blood smear), bone marrow aspirates identified 
only one case of bone marrow failure and none of acute 
leukemia(26)(C).
A recent consensus suggests that the bone marrow aspirate 
is not necessary in children with clinical signs and symptoms 
of ITP, including those under treatment with corticosteroids or 
before splenectomy(15)(D).
Bone marrow aspirate was performed in 72% of 400 children 
with ITP followed up for 10 years and the initial diagnosis was 
not changed in any of the cases(13)(B).
Recommendation: There is no consistent evidence justifying 
the need of a bone marrow examination for ITP diagnosis. 
However, bone marrow aspirate should be performed whenever 
there are changes such as anemia or neutropenia, when there are 
signs/symptoms different from bleeding and prior to prescribing 
corticosteroids.
Which etiological factors are involved in secondary 
immune thrombocytopenia? Which exams 
should be done to investigate primary immune 
thrombocytopenia?
In adult patients with ITP, there is a need for laboratory 
exams as 14% of cases have a secondary etiology. The main 
causes of secondary ITP are infectious diseases (HIV, hepatitis C, 
cytomegalovirus and H. pylori), immune disorders (rheumatoid 
arthritis and anti-phospholipid syndrome), lymphoproliferative 
diseases (non-Hodgkin lymphoma) and post transplantation 
(bone marrow and liver)(27)(C).
In Canada, 198 patients aged between one and 18 years with 
chronic ITP (more than six months) were evaluated regarding 
primary (no identifiable cause except previous viral infection) 
and secondary causes (pre-existing disease such as systemic 
lupus erythematosus or HIV infection); 7.1% of the patients had 
secondary ITP(28)(C).
Comorbidities were observed in 3.9% of 1784 children 
with ITP enrolled in the Pediatric and Adult Registry on Chronic 
ITP. They were aged between three months and 16 years and the 
comorbidities were splenomegaly (1%), gastrointestinal disease 
(0.7%), cardiovascular disease (0.5%), thyroid disease (0.3%), 
cancer (0.2%), diabetes (0.2%), and hypertension (0.06%). Exams 
such as bone marrow aspirate, anti-nuclear antibodies (ANA), HIV 
and hepatitis C are more frequently performed in adults than in 
children (p-value < 0.0001). However, positive results for children 
vs. adults are similar for HIV (1% vs. 1%) and anti-phospholipid 
antibodies (10% vs. 6%) but different for hepatitis C (0% vs. 
3%), H. pylori (17% vs. 31%), anti-nuclear antibodies (18% vs. 
10%) and anti-platelet antibodies (67% vs. 47%). Hepatitis C and 
H. pylori are more common in adults, and anti-nuclear and anti-
platelet antibodies are more often positive in children(29)(B).
There is a 20% increase in risk of H. pylori infection in adults 
with ITP (number needed to harm - NNH: 5)(30)(B). An eight-year 
follow-up of adults with ITP associated with H. pylori infection 
demonstrates maintenance of platelet response after eradication 
therapy(31)(C). In children, the importance of H. pylori is still 
conflicting as most trials were carried out with few patients and 
were not randomized. In the Netherlands, three (6.4%) of 47 patients 
under 16 years with < 100 x 109 platelets/L for more than 1 year 
were infected with H. pylori and, after treatment, two achieved 
partial response (> 50 x 109 platelets/L and increases in platelets to 
twice the baseline level) and one achieved a complete response (> 
150 x 109 platelets/L). Of the 44 children that were negative for H. 
pylori, no complete or partial response was obtained in six months of 
follow-up. The prevalence of H. pylori infection found in this study 
(6.4%) is not statistically different from the prevalence in Dutch 
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children without ITP (10.8%) suggesting that there is no causal 
relation between chronic ITP and H. pylori infection. Improvement 
in platelet count of infected children after H. pylori treatment may 
have occurred due to the natural evolution of ITP(32)(B).
An Italian study of 244 under 18-year-old patients with 
chronic ITP (platelet count < 100 x 109/L for more than 12 months) 
found an incidence of children infected by H. pylori of 20.5% 
(n = 50); 37 received H. pylori treatment. The agent was eradicated 
in 33 (89.2%) patients and platelet counts improved in 39.4% 
(13/33) within one year, while in the H. pylori negative group, 
only 17/166 (10.2%) of the patients had spontaneous remission 
(p-value < 0.005). Of the patients treated for H. pylori infection, 
seven achieved complete response (≥ 150 x 109 platelets/L) and 
six had partial response (≥ 50 x 109 platelets/L). So, patients 
whose H. pylori was successfully eradicated showed increases 
in platelet counts suggesting a need to further investigate the 
relationship between ITP and H. pylori in pediatric patients(33)(B). 
There are two prospective randomized trials assessing 
the relationship of platelet recovery in children with chronic 
ITP following H. pylori eradication. In Thailand, of 55 four- 
to 18-year-old patients with chronic ITP (platelet count 
< 100 x 109/L for more than six months) associated with H. pylori, 
eradication did not increase the response in six months of follow-up 
compared to patients who were not submitted to eradication. The 
prevalence of H. pylori infection was 29.1%(34)(A). In Brazil, the 
prevalence of H. pylori infection in 85 children aged between 2 
and 18 years with chronic ITP (< 150 x 109 platelets/L for over 
six months) was 25.9% (n = 22) and the eradication rate with 
treatment was 92.3%. The results showed high platelet counts in 
patients with chronic ITP after being cured for H. pylori infection 
(57.1%) compared to infected patients that remained untreated 
(0%). The rate of spontaneous recovery of platelet count in non-
infected patients was 33.3%(35)(A).
The association of ITP with cytomegalovirus infection is 
statistically significant (p-value < 0.01); the prevalence of the positive 
antigen in bone marrow is 61.7% with 20.9% being serum IgM 
positive and 86.4% being serum IgG positive. Antigen bone marrow 
positivity is higher in chronic rather than in acute cases (92.3% 
vs. 55.8%), while serum IgM positivity is higher in acute (23.5%) 
rather than in chronic cases (7.7%), but not statistically significant. 
In serum IgG, the positivity is statistically similar in acute (86.7%) 
and chronic cases (84.6%). The patient’s response to the treatment 
of ITP, however, is significantly better in cases that are negative for 
bone marrow antigens compared to those that are positive, while it is 
similar between patients that are positive or negative for serum IgG 
or IgM(36)(B). The presence of cytomegalovirus associated with ITP 
may be related to refractoriness to treatment, but the use of antiviral 
drugs favors a response(37)(C).
An analysis of 31 children (median age eight years) with acute 
and chronic ITP showed that those over 12-years old have a greater 
chance of having positive ANA and antithyroid antibodies (ATA) 
than those under the age of 12 years (p-value < 0.03). In chronic 
ITP, children tend to have more positive ANA and ATA than the 
general pediatric population, but these figures are not statistically 
significant (ANA: p-value = 0.14; ATA: p-value = 0.19). Patients 
with acute ITP who had these autoantibodies at diagnosis are more 
likely to develop chronic ITP. During a two year follow-up, no 
patient developed an autoimmune disease(38)(B).
Data on the relationship between ITP and human 
erythrovirus (parvovirus) B19 infection are scarce. The 
prevalence in 47 newly-diagnosed children was 13%(39)(B), 
while another study including 15 patients did not identify the 
human erythrovirus (parvovirus) B19(40)(C).
There is an association between ITP and exposure to 
certain antibiotics, non-steroidal anti-inflammatory drugs, 
acetaminophen, mucolytics and measles, mumps and rubella 
(MMR) vaccine(41)(A).
Recommendation: On considering the risk of association 
between immune thrombocytopenia and adult infectious 
diseases (hepatitis C, HIV, cytomegalovirus and H. pylori) and 
immunological diseases (antiphospholipid syndrome), as well as 
the benefit of response to treatment in children, it is necessary 
to investigate these diseases with specific tests to establish the 
correct treatment.
Is there evidence of significant bleeding risk related 
to different platelet counts in patients with primary 
immune thrombocytopenia?
The severity of bleeding in children with ITP is inversely 
correlated with the platelet count, irrespective of treatment(42,43)
(B). For example, 97% of all degree 3 bleeding episodes (moderate 
mucosa without the necessity of treatment) and degree 4 bleeding 
(severe mucosa or internal bleeding) occur with platelet counts 
less than 20 x 109/L. In a study of 80 children, when epistaxis was 
degree 2 or higher (mild to severe bleeding), the platelet count 
was less than 10 x 109/L(43)(B). 
Patients with < 10 x 109 platelets/L tend to have more moderate 
to severe bleeding compared to those with more than 10 x 109 
platelets/L. For example, when platelet count is < 10 x 109/L, about 
60% of the cases have mild skin bleeding, while when the platelet 
count is between 10 and 20 x 109/L, no bleeding or skin bleeding 
are observed in 76% of the cases (p-value < 0.01). This observation 
suggests that, in cases of severe thrombocytopenia (< 20 x 109 
platelets/L), an observational approach may not be suitable(44)(B). 
Clinically significant bleeding occurs in 47% of children with ITP 
when the platelet count is < 5 x 109/L, in 26% when the platelet 
count is between 5 and 9 x 109/L, in 13% when it is between 10 and 
19 x 109/L, in 7% between 20 and 50 x 109/L, and when the platelet 
count is over 50 x 109/L, the risk falls to 5%(45)(B).
There is a relationship between the severity of bleeding and 
platelet count in patients between four months and 20 year olds in 
the acute phase of ITP, and there is an increased risk of moderate 
bleeding when the platelet count is below 20 x 109/L(46)(B).
Recommendation: In children with ITP, the intensity of 
bleeding is inversely proportional to the platelet count with 
the suggested critical level for major bleeding complications 
being 20 x 109 platelets/L.
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Is there any correlation between the characteristics 
of primary immune thrombocytopenia and 
thrombocytopenia in newborns?
The prevalence of thrombocytopenia in the newborn of 
mothers with ITP ranges between 15 and 50% for platelet counts 
between 50 x 109/L and 100 x 109/L and between 4.9 and 44% for 
severe thrombocytopenia (< 50 x 109 platelets/L)(47-52)(C)(53)(A).
Evaluations before (67.7%) and during (32.3%) pregnancy 
of 88 women (127 pregnancies) diagnosed with ITP and their 
130 newborns was performed. Mean platelet count of the 
newborns was 216 x 109/L ± 78 x 109/L at birth. However, 
15.4% of them had platelet counts below 100 x 109/L, 8.5% 
were below 50 x 109/L and 2.3% below 20 x 109/L. Only one 
fetus had severe complications with an intrauterine intracranial 
hemorrhage. The influence of several maternal parameters was 
assessed and there was no positive correlation between the 
thrombocytopenia of the newborns and the duration of maternal 
ITP, splenectomy before pregnancy, duration of the mother’s 
ITP, treatment during pregnancy or before the delivery, the 
progressive decline of the platelet count during pregnancy and 
type of delivery. A maternal platelet count < 100 x 109/L at birth 
shows a trend for thrombocytopenia (< 100 x 109 platelets/L) in 
the newborn (p-value = 0.043). The study observed two patterns 
of thrombocytopenia, one at birth and the second a few days 
after birth. Six newborns with normal platelet counts at birth 
developed thrombocytopenia by their 6th day of life(47)(C).
The clinical and laboratory features of 29 newborns were 
evaluated. Of 29 mothers with ITP with a mean age of 28 ± 
5.3 years, 16 (55%) had been diagnosed before the start of 
pregnancy and 13 (45%) during pregnancy. The platelet counts 
at birth of 14 (48%) of the newborns were 9 to 148 x 109/L with 
17% (n = 5) showing mucosal or gastrointestinal bleeding. There 
was no case of intracranial hemorrhage. The main risk factors 
associated to ITP in the newborn were advanced maternal age 
(30 ± 5.3 versus 25.3 ± 3.8 years) and male gender (both p-values 
< 0.05). Maternal thrombocytopenia (< 50 x 109 platelets/L) at 
childbirth, recurrence of ITP during pregnancy and the need 
for platelet transfusion during pregnancy were associated 
with severe newborn thrombocytopenia (p-value < 0.05). 
Splenectomy and drugs prescribed to the mother were not 
correlated to newborn thrombocytopenia, but the sample size 
of this study was small. There was no significant difference 
between newborns with and without thrombocytopenia 
(p-value > 0.05) in respect to whether the mother had positive 
antiplatelet antibodies or not. However, the duration of 
thrombocytopenia in the newborn was higher when the mother 
had platelet autoantibodies(48)(C).
In another study, the mean age of 284 pregnant women 
diagnosed with ITP was 24.8 ± 6.5 years; 38 were diagnosed 
during pregnancy and 62 before pregnancy. Of 286 newborns, 
the platelet count was evaluated in only 212, with 48 (22.6%) 
having < 100 x 109 platelets/L. No case of intracranial 
hemorrhage was observed. Some babies were born with normal 
platelet counts and developed thrombocytopenia within the 
first five days of life. No correlations were found between 
the incidence of newborn thrombocytopenia and the mother’s 
diagnosis (before or during pregnancy), the ITP clinical 
condition (remission does not guarantee that the newborn will 
have a normal platelet count) and the type of treatment during 
pregnancy or at childbirth. Thrombocytopenia prevalence was 
significantly higher in newborns of mothers who maintained 
a complete (> 100 x 109 platelets/L without concomitant 
treatment) or good response (> 100 x 109 platelets/L with 
concomitant treatment) after splenectomy compared to those 
treated with corticosteroids (p-value < 0.01)(49)(C).
In a review of 15 children born to mothers with ITP over 
a ten-year follow-up, the incidence of severe thrombocytopenia 
(< 50 x 109 platelets/L) was 20%; there were no statistically 
significant differences between the mothers who received 
intravenous immunoglobulin before delivery and those 
who did not. No intracranial hemorrhages, seizures or other 
complications were reported in the newborns. Risk factors for 
thrombocytopenia in the newborn were low maternal platelet 
count at childbirth, minimum maternal platelet count during 
pregnancy, history of maternal ITP, IgG level associated 
with low platelet count, and the mother having antiplatelet 
autoantibodies(50)(C).
In the evaluation of 29 pregnant women with ITP and 
their 32 newborns, the mothers’ platelet count at childbirth 
ranged from 9 to 133 x 109/L (mean 81 x 109 platelets/L with 
21% having ≤ 50 x 109 platelets/L). Fourteen newborns (44%) 
presented with thrombocytopenia (< 50 x 109 platelets/L) and 
four (12.5%) with platelet counts between 50 and 150 x 109/L. 
A platelet count below 50 x 109/L in mothers was a predictor for 
thrombocytopenia in the newborn (p-value < 0.027) compared 
to platelet counts above 50 x 109/L. The treatment of maternal 
ITP with prednisone did not show significant effects on the 
newborn’s platelet count(51)(C).
None of 61 babies born to 50 mothers with ITP diagnosed 
before or during pregnancy suffered from thrombocytopenia-
related death or disease; 4.9% had platelet counts lower than 
50 x 109/L. There was a drop in the platelet count after birth 
in 66% of the newborns. Moreover, there was no association 
between thrombocytopenia in the newborn and the maternal 
platelet count, maternal treatment with corticosteroids, IgG 
levels associated with platelets and splenectomy(52)(C).
A comparison of 28 newborns of mothers with ITP 
treated with low doses of betamethasone from the 37th week 
of gestation until birth and untreated mothers showed that the 
mean platelet counts of the mothers at childbirth were 99 x 
109/L and 95 x 109/L, respectively (p-value > 0.05). Between 
the two groups of newborns, there was no significant difference 
in the platelet count, with 14.2% of each group having severe 
thrombocytopenia (< 50 x 109 platelets/L). Thrombocytopenia 
between 50 x 109 platelets/L and 150 x 109 platelets/L was 
observed in 50% of the newborns in the group of treated mothers 
and 42.8% of the untreated mothers. Some patients developed 
thrombocytopenia on the 4th day of life. The prevalences of 
neonatal thrombocytopenia were 64% and 57% in the treated 
and untreated groups, respectively. The number of bleeding 
complications was similar in both groups. Therefore maternal 
treatment with low-dose corticosteroid does no not prevent 
thrombocytopenia or bleeding in newborns(53)(A).
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Recommendation: There is no correlation between the incidence 
of thrombocytopenia in the newborn and the duration of maternal 
ITP, the mothers’ clinical conditions, splenectomy before 
pregnancy, treatment during pregnancy or before delivery, and 
delivery type. The risk factors found for thrombocytopenia in 
the newborn were the severity of mother’s thrombocytopenia 
at delivery (< 50 x 109 platelets/L), maternal age, male gender 
and the presence of antiplatelet autoantibodies. It is essential to 
monitor the newborn in the early days of life due to the possibility 
of transient thrombocytopenia which may become severe.
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Appendix
Search strategies by question for the clinical guidelines for 
primary immune thrombocytopenia in children and adolescents 
- diagnosis
When is primary immune thrombocytopenia considered 
acute, chronic or persistent?
(Purpura, Thrombocytopenic, Idiopathic OR Werlhof Disease 
OR Autoimmune Thrombocytopenic Purpura OR Purpura, 
Thrombocytopenic) AND ((CLASSIFICATION) OR (time 
factors) OR (International Classification of Diseases) OR (phases) 
OR (chronic AND acute)) 
What are the criteria that must be present for the definition 
of refractory primary immune thrombocytopenia and for 
complete and partial remission?
(Purpura, Thrombocytopenic, Idiopathic OR Werlhof Disease 
OR Autoimmune Thrombocytopenic Purpura OR Purpura, 
Thrombocytopenic OR Immune Thrombocytopenia) AND (long-
term OR treatment outcome OR response OR refractory OR 
remission OR relapsed OR relapsing OR criteria OR definition) 
AND (platelet OR title OR etiology/broad [filter] OR prognosis/
broad [filter] OR therapy/broad [filter] OR epidemiologic 
methods OR comparative study) 
When should the primary immune thrombocytopenia 
diagnosis in a patient with thrombocytopenia be 
considered? At what platelet count should primary immune 
thrombocytopenia be investigated?
(Purpura, Thrombocytopenic, Idiopathic OR Werlhof Disease 
OR Autoimmune Thrombocytopenic Purpura OR Purpura, 
Thrombocytopenic OR Immune Thrombocytopenia) AND 
platelet AND diagnosis/broad [filter] 
Is there evidence to support bone marrow examination to 
confirm diagnosis of primary immune thrombocytopenia? 
When is bone marrow examination indicated?
(Purpura, Thrombocytopenic, Idiopathic OR Werlhof Disease 
OR Autoimmune Thrombocytopenic Purpura OR Purpura, 
Thrombocytopenic OR Immune Thrombocytopenia OR 
Thrombocytopenia) AND (Bone Marrow OR Bone Marrow 
Cells OR Bone Marrow Examination OR bone marrow biopsy 
OR bone marrow aspiration OR bone marrow aspirate) AND 
(Diagnosis/broad [filter] OR Diagnosis [filter]) 
Which etiological factors are involved in secondary immune 
thrombocytopenia (or secondary immune thrombocytopenic 
purpura)? Which exams should be done to investigate 
primary immune thrombocytopenia?
(Purpura, Thrombocytopenic, Idiopathic OR Werlhof Disease 
OR Autoimmune
Thrombocytopenic Purpura OR Purpura, Thrombocytopenic 
OR Immune Thrombocytopenia) AND (HIV OR Hepatitis OR 
Cytomegalovirus OR Helicobacter pylori OR rheumatic disease 
OR Antiphospholipid Syndrome OR Thyrotropin OR Neoplasms 
OR Blood cell count) AND (etiology/broad[filter] OR diagnosis/
broad[filter])
Is there evidence of significant bleeding risk related to 
different platelet counts in patients with primary immune 
thrombocytopenia?
 (Purpura, Thrombocytopenic, Idiopathic OR Werlhof Disease 
OR Autoimmune Thrombocytopenic Purpura OR Purpura, 
Thrombocytopenic OR Immune Thrombocytopenia) AND 
(Hospitalization OR admission OR hospital OR hospitalized)
Is there any correlation between the characteristics of 
primary immune thrombocytopenia and thrombocytopenia 
in newborns?
(Postnatal Care OR Infant, Newborn) AND (Purpura, 
Thrombocytopenic, Idiopathic OR Werlhof Disease OR 
Autoimmune Thrombocytopenic Purpura OR Purpura, 
Thrombocytopenic)
